Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 21, 2021

SELL
$13.07 - $18.84 $180,836 - $260,670
-13,836 Closed
0 $0
Q2 2021

Jul 29, 2021

SELL
$16.52 - $20.4 $4,163 - $5,140
-252 Reduced 1.79%
13,836 $238,000
Q1 2021

May 13, 2021

BUY
$16.56 - $25.46 $233,297 - $358,680
14,088 New
14,088 $282,000
Q4 2020

Jan 22, 2021

SELL
$15.77 - $19.03 $355,708 - $429,240
-22,556 Closed
0 $0
Q3 2020

Oct 14, 2020

BUY
$16.59 - $24.79 $374,204 - $559,163
22,556 New
22,556 $372,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $157M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Avantax Advisory Services, Inc. Portfolio

Follow Avantax Advisory Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Advisory Services, Inc. with notifications on news.